ConductScience.org, home

Paper35638331

Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.

Yagyu H and 1 other. J Diabetes Investig, 2022. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. Papers, record 35638331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35638331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.
PubMed
Journal
J Diabetes Investig
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.31
iCite
Revised in PubMed
2025-01-03
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yagyu HHiroakihttps://orcid.org/0000-0003-3518-6530
2Shimano HHitoshi

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cardiovascular DiseasesMajor topic
Diabetes Mellitus, Type 2Major topic
Sodium-Glucose Transporter 2 InhibitorsMajor topic
Fruit
Glucose
Humans
Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor Agonists

Source PubMed

Download CSV of topics

References152

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125088437Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.Lancet2014https://conductscience.org/library/papers/25088437PubMed
221664294Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.Vascul Pharmacol2011https://conductscience.org/library/papers/21664294PubMed
312876091Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.JAMA2003https://conductscience.org/library/papers/12876091PubMed
421205121Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.Diabetes Obes Metab2011https://conductscience.org/library/papers/21205121PubMed
534364771Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.Nutr Metab Cardiovasc Dis2021https://conductscience.org/library/papers/34364771PubMed
628431667The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.Diabetes Metab2017https://conductscience.org/library/papers/28431667PubMed
726179504Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial.Lancet Diabetes Endocrinol2015https://conductscience.org/library/papers/26179504PubMed
834893404All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials.Nutr Metab Cardiovasc Dis2022https://conductscience.org/library/papers/34893404PubMed
931748169Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial.Lancet Diabetes Endocrinol2019https://conductscience.org/library/papers/31748169PubMed
1035050311Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials.Diabetes2022https://conductscience.org/library/papers/35050311PubMed
1121366474Diabetes mellitus, fasting glucose, and risk of cause-specific death.N Engl J Med2011https://conductscience.org/library/papers/21366474PubMed
1220427682Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.Diabetes Care2010https://conductscience.org/library/papers/20427682PubMed
1330424892SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet2019https://conductscience.org/library/papers/30424892PubMed
1426343814Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.Diabetes Obes Metab2015https://conductscience.org/library/papers/26343814PubMed
1520937686A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study.Diabetes Care2011https://conductscience.org/library/papers/20937686PubMed
1630259238Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?Curr Cardiol Rep2018https://conductscience.org/library/papers/30259238PubMed
1728402770Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.N Engl J Med2017https://conductscience.org/library/papers/28402770PubMed
1823230096Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.Diabetes Care2013https://conductscience.org/library/papers/23230096PubMed
1923992602Alogliptin after acute coronary syndrome in patients with type 2 diabetes.N Engl J Med2013https://conductscience.org/library/papers/23992602PubMed
2030415602Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med2019https://conductscience.org/library/papers/30415602PubMed

See all 152 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
40883386Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study.Sci Rep2025https://conductscience.org/library/papers/40883386PubMed
40540523PPARγ inhibitors enhance the efficacy of statin therapy for steroid-induced osteonecrosis of the femoral head by directly inhibiting apoptosis and indirectly modulating lipoprotein subfractions.PLoS One2025https://conductscience.org/library/papers/40540523PubMed
38389209Interplay of cardiovascular health and diabetes: Insights into weight management and risk reduction.J Diabetes Investig2024https://conductscience.org/library/papers/38389209PubMed
36631991Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus.Diabetes Metab J2023https://conductscience.org/library/papers/36631991PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35638331

GET https://conductscience.org/api/papers/v1/35638331/references?page=2